SG
SGBAF
SES S.A.
$9.85
+1.55%
No data for this timeframe.
Vol
SEC Reports3
Recent Activity
May 13, 2026
SEC
SES reported Q1 2026 revenue of €847M (+66.6% reported, +3.1% like-for-like at constant FX) and Adjusted EBITDA of €404M
6-K — Impact 5/10
Apr 1, 2026
SEC
SES S.A. reported strong financial growth in 2025, driven by the acquisition of Intelsat, which significantly increased
20-F — Impact 7/10
Mar 27, 2026
SEC
SES S.A. completed a cash tender offer for its deeply subordinated securities, purchasing 326,984,000 EUR of the 625,000
6-K — Impact 4/10
Analyst Ratings
4Strong Buy
8Buy
5Hold
1Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 28, 2021 | Berenberg | UPGRADE | Hold → Buy |
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.3/10.
NEUTRAL
6-K
5/10
SES reported Q1 2026 revenue of €847M (+66.6% reported, +3.1% like-for-like at constant FX) and Adju
May 13, 2026
MIXED
20-F
7/10
SES S.A. reported strong financial growth in 2025, driven by the acquisition of Intelsat, which sign
Apr 1, 2026
NEUTRAL
6-K
4/10
SES S.A. completed a cash tender offer for its deeply subordinated securities, purchasing 326,984,00
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2021): 67% buy across 18 analysts — 4 strong buy, 8 buy, 5 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.9B | 83.6% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.8B | 8.3% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $3.4B | 31.3% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $3.5B | 0.7% | — |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 28, 2021 | Berenberg | UPGRADE | Hold | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 8 | 5 | 1 | 0 | 67% | |
| Apr 1, 2026 | 5 | 7 | 5 | 1 | 0 | 67% | |
| Mar 1, 2026 | 5 | 6 | 5 | 1 | 0 | 65% | |
| Feb 1, 2026 | 5 | 6 | 5 | 1 | 0 | 65% | |
| Jan 1, 2026 | 4 | 6 | 5 | 1 | 0 | 63% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.